H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Alumis (ALMS) to $25 from $40 and keeps a Buy rating on the shares. The firm says the oral psoriasis drug market “now looks materially more competitive.” Protagonist’s (PTGX) icotrokinra now holds the strongest overall commercial position, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
- Alumis price target raised to $38 from $33 at Morgan Stanley
- Alumis files automatic mixed securities shelf
- Alumis initiated with a Strong Buy at Raymond James
- TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis